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Introduction
Chronic uveitis is associated with JIA in about 15–30% of
cases. Treatment with anti-TNF agents is very effective in
JIA, but their efficacy for uveitis is controversial. We
present here the preliminary results of a retrospective case
series of uveitis associated of JIA and treated by different
anti-TNF.
Objective
To evaluate the efficacy of TNF inhibitors in JIA-associated
uveitis, as well as report the cases of uveitis associated with
the use of anti-TNF.
Methods
The data of 16 patients with JIA and uveitis receiving anti-
TNF were collected retrospectively in three French centers.
Results
Of the 16 patients, 10 were treated with etanercept
(62.5%), 1 with adalimumab (6.25%), and 5 (31.2%)
with infliximab. Notably, two cases of uveitis were associ-
ated with use of etanercept. In 5 patients (31.2%) the anti-
TNF was changed because of lack of efficacy and/or side
effects to another one (in 4/5 adalimumab). Ten patients
had a complicated uveitis (cataract in 5). The number of
relapses of uveitis was 4 ± 1.35 with the first anti-TNF, and
1.3 ± 1.5 with the second one. Remission of uveitis was
obtained in 4 cases, 3 of them with adalimumab and one
case with etanercept.
Conclusion
Anti-TNF agents have a favourable effect in JIA-associated
uveitis, but adalimumab and perhaps infliximab may be
more effective than etanercept, during which treatment
uveitis may even develop.
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